Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 24, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Awarded Patent for Its Experimental Individualized Immunotherapy for the Treatment of HIV Infection

DURHAM, N.C., Aug. 24, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
August 12, 2015 16:05 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Reports Second Quarter 2015 Financial Results and Operational Highlights

- Independent Data Monitoring Committee (IDMC) Recommended Continuation of Pivotal Phase 3 ADAPT Clinical Trial of AGS-003 - - Completed Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial...
August 10, 2015 13:00 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Announces Pilot Clinical Trial of AGS-003 as Neoadjuvant Immunotherapy for Localized Renal Cell Carcinoma

DURHAM, N.C., Aug. 10, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
August 05, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Hold Second Quarter 2015 Financial Results Conference Call on Wednesday, August 12, 2015

DURHAM, N.C., Aug. 5, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (NASDAQ:ARGS), an immuno-oncology company focused on the development and commercialization of fully individualized...
July 21, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Announces Formation of Scientific Advisory Board

DURHAM, N.C., July 21, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully individualized...
July 17, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Present at 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention

The company's director of molecular biology to participate in roundtable discussion at the "Towards an HIV Cure" symposium DURHAM, N.C., July 17, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc....
July 15, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Announces Completion of Patient Enrollment in Pivotal Phase 3 ADAPT Clinical Trial of AGS-003

DURHAM, N.C., July 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
June 16, 2015 16:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics to Present at the 2015 JMP Securities Life Sciences Conference

DURHAM, N.C., June 16, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of fully personalized...
June 15, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Argos Therapeutics Hires John D. Menditto as Vice President of Corporate Communications and Investor Relations

DURHAM, N.C., June 15, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...
June 04, 2015 08:30 ET | Source: Argos Therapeutics, Inc.

Independent Data Monitoring Committee Recommends Continuation of Pivotal ADAPT Phase 3 Clinical Trial of AGS-003 for Metastatic Renal Cell Carcinoma

DURHAM, N.C., June 4, 2015 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc. (Nasdaq:ARGS) ("Argos"), an immuno-oncology company focused on the development and commercialization of fully personalized...